The Lee Lab group photo at the Fred Hutchinson Cancer Research Center in Seattle, Washington on July 11, 2017.
Dr. Stephanie Lee and her staff are located at Fred Hutchinson Cancer Research Center. Our work focuses on hematopoietic cell transplant (HCT) patients and chronic graft-versus-host disease (GVHD). Dr. Lee is the lead investigator and Fred Hutchinson Cancer Research Center is the coordinating center for the Chronic Graft-versus-Host Disease Consortium.This is funded by the National Cancer Institute.
Survivors of HCT may have more late effects, worse quality of life, and a shortened lifespan compared to people who do not undergo HCT. In people who receive stem cells from another person, unique immune mediated disorders such as chronic GVHD take a particularly high toll. Although patients may experience symptoms and organ dysfunction resembling known autoimmune syndromes or solid organ allograft rejections, the underlying biology is poorly characterized. Dr. Lee’s research program is devoted to understanding late effects and chronic GVHD, and developing better approaches to the prevention, diagnosis and treatment of these transplant-related problems.
Dr. Lee's research emphasizes survivorship challenges, quality-of-life issues, and the impact of chronic GVHD. Another area of interest is health-services research, which includes analysis of physician practices, doctor-patient communication, cost-effectiveness analysis, and similar policy issues.
In addition to her research projects, Dr. Lee is also the Research Director of the Long-Term-Follow-Up Program (LTFU) at Fred Hutchinson Cancer Research Center. This program follows more than 5,000 HCT survivors.